OMD is increasingly diagnosed in prostate cancer (PCa) owing on the one hand to improved detection with advanced imaging like prostate-specific membrane antigen (PSMA) PET-CT and on the other hand to the success of systemic therapies in prolonging cancer survival. This evidence concerns the gene FOLH1 and posterior cortical atrophy.